124 related articles for article (PubMed ID: 31569304)
1. Bosutinib Acts as a Tumor Inhibitor via Downregulating Src/NF-κB/Survivin Expression in HeLa Cells.
Yu L; Guo W; Liu L; Zhang G; Zhang F; Qu Y; Liu Y; Li H; Li H
Anat Rec (Hoboken); 2019 Dec; 302(12):2193-2200. PubMed ID: 31569304
[TBL] [Abstract][Full Text] [Related]
2. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
[TBL] [Abstract][Full Text] [Related]
3. Second-generation Src/Abl inhibitor bosutinib effectively induces apoptosis in human esophageal squamous cell carcinoma (ESCC) cells via inhibiting Src/Abl signaling.
Ha YNE; Dai Y; Wufuer D; Pidayi M; Anasihan G; Chen L
Neoplasma; 2020 Jan; 67(1):54-60. PubMed ID: 31777258
[TBL] [Abstract][Full Text] [Related]
4. Src as a Therapeutic Target in Biliary Tract Cancer.
Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Mol Cancer Ther; 2016 Jul; 15(7):1515-24. PubMed ID: 27196758
[TBL] [Abstract][Full Text] [Related]
5. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
Segrelles C; Contreras D; Navarro EM; Gutiérrez-Muñoz C; García-Escudero R; Paramio JM; Lorz C
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933569
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
Messersmith WA; Rajeshkumar NV; Tan AC; Wang XF; Diesl V; Choe SE; Follettie M; Coughlin C; Boschelli F; Garcia-Garcia E; Lopez-Rios F; Jimeno A; Hidalgo M
Mol Cancer Ther; 2009 Jun; 8(6):1484-93. PubMed ID: 19509264
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous inhibition of c-Abl and Src kinases abrogates the exaggerated expression of profibrotic genes in cultured systemic sclerosis dermal fibroblasts.
Piera-Velazquez S; Jimenez SA
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):36-44. PubMed ID: 30277861
[TBL] [Abstract][Full Text] [Related]
8. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
9. Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors.
Beetham H; Griffith BGC; Murina O; Loftus AEP; Parry DA; Temps C; Culley J; Muir M; Unciti-Broceta A; Sims AH; Byron A; Brunton VG
Cancer Res; 2022 Feb; 82(4):632-647. PubMed ID: 34921014
[TBL] [Abstract][Full Text] [Related]
10. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
Wermuth PJ; Jimenez SA
PLoS One; 2018; 13(5):e0196559. PubMed ID: 29718973
[TBL] [Abstract][Full Text] [Related]
11. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
Vultur A; Buettner R; Kowolik C; Liang W; Smith D; Boschelli F; Jove R
Mol Cancer Ther; 2008 May; 7(5):1185-94. PubMed ID: 18483306
[TBL] [Abstract][Full Text] [Related]
12. Bosutinib.
Keller G; Schafhausen P; Brümmendorf TH
Recent Results Cancer Res; 2010; 184():119-27. PubMed ID: 20072835
[TBL] [Abstract][Full Text] [Related]
13. Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.
Isfort S; Crysandt M; Gezer D; Koschmieder S; Brümmendorf TH; Wolf D
Recent Results Cancer Res; 2018; 212():87-108. PubMed ID: 30069626
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Lidocaine and Bosutinib on 4T1 Murine Breast Cancer Cell Behaviour
Wall TP; Crowley PD; Buggy DJ
Anticancer Res; 2021 Jun; 41(6):2835-2840. PubMed ID: 34083273
[TBL] [Abstract][Full Text] [Related]
15. Bosutinib, an SRC inhibitor, induces caspase-independent cell death associated with permeabilization of lysosomal membranes in melanoma cells.
Noguchi S; Shibutani S; Fukushima K; Mori T; Igase M; Mizuno T
Vet Comp Oncol; 2018 Mar; 16(1):69-76. PubMed ID: 28371355
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.
Taylor JW; Dietrich J; Gerstner ER; Norden AD; Rinne ML; Cahill DP; Stemmer-Rachamimov A; Wen PY; Betensky RA; Giorgio DH; Snodgrass K; Randall AE; Batchelor TT; Chi AS
J Neurooncol; 2015 Feb; 121(3):557-63. PubMed ID: 25411098
[TBL] [Abstract][Full Text] [Related]
17.
Hu S; Xie D; Zhou P; Liu X; Yin X; Huang B; Guan H
Int J Mol Med; 2021 May; 47(5):. PubMed ID: 33693953
[TBL] [Abstract][Full Text] [Related]
18. Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src.
Sakuma Y; Takeuchi T; Nakamura Y; Yoshihara M; Matsukuma S; Nakayama H; Ohgane N; Yokose T; Kameda Y; Tsuchiya E; Miyagi Y
J Pathol; 2010 Apr; 220(5):574-85. PubMed ID: 20146241
[TBL] [Abstract][Full Text] [Related]
19. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
Keller G; Schafhausen P; Brummendorf TH
Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
[TBL] [Abstract][Full Text] [Related]
20. A phosphoproteomics approach to identify candidate kinase inhibitor pathway targets in lymphoma-like primary cell lines.
Vojvodic M; Hansford LM; Morozova O; Blakely KM; Taylor P; Fathers KE; Moffat J; Marra M; Smith KM; Moran MF; Kaplan DR
Curr Drug Discov Technol; 2013 Dec; 10(4):283-304. PubMed ID: 23701117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
